This article is compiled from Professor Song Zhengbo of Zhejiang Provincial Cancer Hospital.“Current Status and Development Challenges of ADC Drugs”. Song Zhengbo Doctor of Oncology, Associate Chief Physician, Associate Professor, Master’s Supervisor More than 100 years ago, the father of immunology, Paul Ehrlich, first proposed the concept of “magic bullet,” which refers to selectively delivering … Read more
Introduction Despite rapid advancements in targeted therapy for NSCLC (non-small cell lung cancer), there remains an unmet need. This article summarizes the latest progress in targeted therapies for NSCLC involving Her2, Her3, and Trop-2 to inform readers. NSCLC and ADC Whether through targeted therapy or immunotherapy, the number of lung cancer patients benefiting remains limited, … Read more
Introduction Zongertinib (BI1810631) is a selective HER2 (ERBB2) tyrosine kinase inhibitor (TKI) developed by Boehringer Ingelheim, which covalently binds to the receptor tyrosine kinase domain (TKD) of HER2 exon 20 mutations. This selectivity allows it to block only the abnormal downstream signaling of HER2 without affecting the wild-type epidermal growth factor receptor (wtEGFR, i.e., normal … Read more
Source: Professor Zhang Bo The activation mechanisms of the HER-2 gene include amplification, mutation, insertion, and protein overexpression. Although HER-2 is considered a driver gene in lung cancer, no targeted therapeutic drugs have been approved. Recently, Lancet Oncology published efficacy and safety data for the ADC drug DS-8201 targeting HER2 in patients with advanced NSCLC … Read more
Updates on the first human study data from Phase I/II show that B7-H3 targeted ADCs continue to demonstrate therapeutic potential. In recent years, antibody-drug conjugates (ADCs) have emerged as a new class of drugs that bring new “hope” to the treatment of advanced cancer patients due to their unique mechanisms of action. The B7 family … Read more